Loading stock data…
$1.05-0.02 (-1.87%)
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
Imunon, Inc. in the Healthcare sector is trading at $1.05 with a market capitalization of $8M. Wall Street consensus targets $17.00 (5 analysts), implying a +1519.0% move over the next 12 months. The stock is currently near its 52-week low of $0.96, remaining 56.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$4.31M↓ | -$4.26M↓ | -$3.48M↓ | -$2.77M |
| Net Income | — | -$4.25M↓ | -$4.22M↓ | -$3.43M↓ | -$2.74M |
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the loca...